| Literature DB >> 16451718 |
Robert K Browne1, Hong Li, Jessica Seratt, Andrew Kouba.
Abstract
Combinations of progesterone, lutenizing hormone releasing hormone analogue (LHRHa), human chorionic gonadotrophin (hCG), and the dopamine-2 (DA2) receptor antagonist 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one (Pimozide; Orap) were tested for improvement of spawning rates, oocyte numbers, fertilization and neurulation rates of the Fowler toad (Bufo fowleri). Only treatments combined with progesterone produced large numbers of oocytes. The best treatment on oocyte numbers, neurulation rates, and the number of neurulas was with 5 mg progesterone, 20 mic.g LHRHa, and 0.25 mg Pimozide. Progesterone (5 mg) with 60 mic.g LHRHa gave high spawning rates, oocyte numbers, and fertilization rates but neurulation rates were low. Progesterone alone in high repeated doses did not result in ovulation. High doses of LHRHa (60 mic.g) with hCG, progesterone, and Pimozide gave the greatest number of toads spawning, however, they resulted in low oocyte numbers, fertilization and neurulation rates. A low dose of LHRHa (4 mic.g) with hCG, or hCG alone as a second administration, and progesterone with Pimozide produced few good quality oocytes. Toads were given normal ovulatory doses of hormones 24 or 48 hrs after their initial dose, but these resulted in low oocyte numbers followed by poor fertilization. Overall, these results suggest that progesterone with a dose between 20 mic.g and 60 mic.g of LHRHa may be optimal for the induction of ovulation in these toads. Moreover, Pimozide can supplement low doses of LHRHa but not replace it.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16451718 PMCID: PMC1373633 DOI: 10.1186/1477-7827-4-3
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Toads were randomly placed into seven treatments where hormones were administered alone or in variouscombinations. Treatment 7* was administered two doses of progesterone 12 hrs apart. Then all seven treatments were administered a second dose of compounds either 24 or 48 hrs later and evaluated as a second set of treatments (8–14).
| Treatment | No. of animals | Hormones administered (First combination) | Period (hrs) | Treatment | Hormones administered (Second combination) |
| 1 | 7 | 500 IU hCG + 4 μg LHRHa | 24 | 8 | 500 IU hCG + 4 μg LHRHa |
| 2 | 7 | 20 μg LHRHa | 24 | 9 | 60 μg LHRHa |
| 3 | 7 | 20 μg LHRHa + 0.25 mg Pimozide™+ 5 mg progesterone | 24 | 10 | 60 μg LHRHa |
| 4 | 7 | 20 μg LHRHa + 0.25 mg Pimozide™ | 24 | 11 | 60 μg LHRHa |
| 5 | 7 | 60 μg LHRHa + 5 mg progesterone | 24 | 12 | 60 μg LHRHa |
| 6 | 7 | 60 μg LHRHa + 5 mg progesterone + 0.25 mg Pimozide™ + 500 IU hCG | 24 | 13 | 500 IU hCG |
| 7* | 5 | 5 mg progesterone > 12 h r > 5 mg progesterone | 48 | 14 | 60 μg LHRHa |
The different doses of hormones or Pimozide™ used in this study and the amountper. gram of toad weight.
| Compound | Administered dose | Amount per gram of toad weight |
| hCG | 500 IU hCG | 15 IU |
| LHRHa | 4 μg | 0.12 μg |
| LHRHa | 20 μg | 0.61 μg |
| LHRHa | 60 μg | 1.8 μg |
| Progesterone | 5 mg | 0.15 mg |
| Pimozide™ | 0.25 mg | 0.0076 mg |
Variables measured in response to different hormone treatments including toad length, weight, the number and percentage of spawning toads, the number of oocytes, percent fertilization, number of neurulas, percent neurulation, and total number of neurulas. Treatment 7* was administered two doses of progesterone 12 hrs apart. Data in the table are expressedas Means ± SE and ranges of spawning toads.
| Treatment | Treatment | Length (mm) | Weight (g) | No. and percent of toads spawning | No. oocytes per. spawning toad | Total oocytes | Percent fertilization | Neurulas | Percent neurulation | Total neurulas |
| 1 | 500 IU hCG + 4 μg LHRHa | 63.5 ± 6.7 | 48.0 ± 18.0 | (2/7) 29% | 2283 ± 269 | 4566 | 0% | 0 | 0% | 0 |
| 2 | 20 μg LHRHa | 69.4 ± 8.5 | 50.2 ± 17.9 | (0/7) 0% | NA | 0 | NA | NA | NA | NA |
| 3 | 20 μg LHRHa + 0.25 mg Pimozide™ + 5 mg progesterone | 70.0 ± 8.0 | 48.8 ± 11.4 | (4/7) 58% | 2486 ± 825 (350–4140) | 9944 | 35 ± 11% (0–69%) | 546 ± 60 (0–1131) | 22 ± 12% (0–53%) | 2184 |
| 4 | 20 μg LHRHa + 0.25 mg Pimozide™ | 65.9 ± 4.5 | 43.5 ± 5.7 | (1/7) 14% | 627 | 627 | 34% | 157 | 25% | 157 |
| 5 | 60 μg LHRHa + 5 mg progesterone | 67.1 ± 4.7 | 46.0 ± 6.1 | (5/7) 71% | 2004 ± 196 (1489–2625) | 10020 | 73 ± 5% (57–89%) | 378 ± 106 (0–1081) | 19 ± 11% (0–60%) | 1890 |
| 6 | 60 μg LHRHa + 5 mg progesterone + 0.25 mg Pimozide™ + 500 IU hCG | 65.1 ± 5.0 | 43.2 ± 7.2 | (6/7) 85% | 1078 ± 502 (80–3470) | 6468 | 20 ± 8% (0–47%) | 129 ± 31 (0–178) | 12 ± 5% (0–34%) | 774 |
| 7* | 5 mg progesterone then after 12 hrs another 5 mg progesterone | 64.0 ± 2.8 | 40.0 ± 5.3 | (0/5) 0% | NA | 0 | NA | NA | NA | NA |
Variables measured in response to a second administration of hormones 24 to 48 hrs after the first set of treatments include the number and percentage of spawning toads, the number of eggs, percentage fertilization, number of neurulas, percentage neurulation, and total number of neurulas. Data in the table are expressed as Means ± SE and ranges of spawning toads.
| Treatment | Treatment | % Spawn | No. oocytes | % cleavage | Neurulas | % neurulation | Total neurulas |
| 8 | 500 IU hCG + 4 μg LHRHa | 0/7 0% | NA | NA | NA | NA | NA |
| 9 | 60 μg LHRHa | 0/7 0% | NA | NA | NA | NA | NA |
| 10 | 60 μg LHRHa | 0/7 0% | NA | NA | NA | NA | NA |
| 11 | 60 μg LHRHa | 1/7 14% | 200 | 87% | 0 | 0% | 0 |
| 12 | 500 IU hCG | 3/7 42% | 68 ± 50 (13–110) | 0% | 0 | 0% | 0 |
| 13 | 500 IU hCG | 2/7 29% | 160 ± 28 (60–100) | 0% | 0 | 0% | 0 |
| 14* | 60 μg LHRHa | 0/5 0% | NA | NA | NA | NA | NA |